Shanghai Pioneer Holding Management
Management Kriterienprüfungen 3/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Steven Yang
Geschäftsführender
CN¥655.0k
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 78.8% |
| Amtszeit als Geschäftsführer | 1.2yrs |
| Eigentum des Geschäftsführers | n/a |
| Durchschnittliche Amtszeit des Managements | 4yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 2.5yrs |
Jüngste Management Updates
Recent updates
Shanghai Pioneer Holding's (HKG:1345) Dividend Will Be CN¥0.024
Apr 24
Shanghai Pioneer Holding (HKG:1345) Will Pay A Dividend Of CN¥0.024
Apr 03Shanghai Pioneer Holding's (HKG:1345) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 01Shanghai Pioneer Holding Ltd (HKG:1345) Could Be Riskier Than It Looks
Mar 22Shanghai Pioneer Holding (HKG:1345) Is Finding It Tricky To Allocate Its Capital
Feb 26Does Shanghai Pioneer Holding (HKG:1345) Have A Healthy Balance Sheet?
Oct 21Shanghai Pioneer Holding (HKG:1345) Has Announced That It Will Be Increasing Its Dividend To CN¥0.024
Sep 18Shanghai Pioneer Holding (HKG:1345) Is Increasing Its Dividend To CN¥0.024
Sep 01Here's Why We Think Shanghai Pioneer Holding (HKG:1345) Is Well Worth Watching
Aug 09Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Apr 14Shanghai Pioneer Holding's (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 31Shanghai Pioneer Holding (HKG:1345) Seems To Use Debt Rather Sparingly
Dec 15China Pioneer Pharma Holdings' (HKG:1345) Dividend Will Be Reduced To CN¥0.018
Sep 21China Pioneer Pharma Holdings' (HKG:1345) Shareholders Will Receive A Smaller Dividend Than Last Year
Sep 02China Pioneer Pharma Holdings (HKG:1345) Has More To Do To Multiply In Value Going Forward
Jun 22China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.064
Apr 14China Pioneer Pharma Holdings (HKG:1345) Will Be Hoping To Turn Its Returns On Capital Around
Jan 16These 4 Measures Indicate That China Pioneer Pharma Holdings (HKG:1345) Is Using Debt Safely
Oct 11China Pioneer Pharma Holdings (HKG:1345) Is Paying Out Less In Dividends Than Last Year
Sep 15China Pioneer Pharma Holdings (HKG:1345) Has Announced That Its Dividend Will Be Reduced To HK$0.056
Sep 01China Pioneer Pharma Holdings (HKG:1345) Will Be Looking To Turn Around Its Returns
Aug 26Returns On Capital At China Pioneer Pharma Holdings (HKG:1345) Paint A Concerning Picture
May 22We Think China Pioneer Pharma Holdings (HKG:1345) Can Stay On Top Of Its Debt
Apr 25Can Mixed Financials Have A Negative Impact on China Pioneer Pharma Holdings Limited's 's (HKG:1345) Current Price Momentum?
Mar 14How Has China Pioneer Pharma Holdings (HKG:1345) Allocated Its Capital?
Feb 21
Should You Use China Pioneer Pharma Holdings' (HKG:1345) Statutory Earnings To Analyse It?
Feb 03Is China Pioneer Pharma Holdings Limited (HKG:1345) At Risk Of Cutting Its Dividend?
Jan 16China Pioneer Pharma Holdings (HKG:1345) Has A Rock Solid Balance Sheet
Dec 29Is China Pioneer Pharma Holdings Limited's (HKG:1345) Stock Price Struggling As A Result Of Its Mixed Financials?
Dec 14China Pioneer Pharma Holdings (HKG:1345) Has Gifted Shareholders With A Fantastic 124% Total Return On Their Investment
Nov 29Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Dec 31 2023 | CN¥655k | CN¥516k | CN¥146m |
| Sep 30 2023 | n/a | n/a | CN¥168m |
| Jun 30 2023 | n/a | n/a | CN¥190m |
| Mar 31 2023 | n/a | n/a | CN¥213m |
| Dec 31 2022 | CN¥752k | CN¥624k | CN¥235m |
Vergütung im Vergleich zum Markt: StevenDie Gesamtvergütung ($USD90.43K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD414.20K).
Entschädigung vs. Einkommen: StevenDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Steven Yang (36 yo)
1.2yrs
Amtszeit
CN¥655,000
Vergütung
Mr. Yuewen Yang, also known as Steven, serves as Chief Executive Officer since April 2023 and serves as its Executive Director since September 16, 2022 and served as Chief Operating Officer at Shanghai Pio...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Executive Chairman | 11.3yrs | CN¥2.05m | 0.95% CN¥ 21.1m | |
| CEO & Executive Director | 1.2yrs | CN¥655.00k | keine Daten | |
| General Manager of Dental Business Division & Executive Director | 2.8yrs | CN¥717.00k | keine Daten | |
| Chief Financial Officer | 7.5yrs | keine Daten | keine Daten | |
| General Manager of Investment Unit | no data | keine Daten | keine Daten | |
| Company Secretary | 5.3yrs | keine Daten | keine Daten |
4.0yrs
Durchschnittliche Betriebszugehörigkeit
49yo
Durchschnittliches Alter
Erfahrenes Management: 1345Das Führungsteam des Unternehmens gilt als erfahren (4 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Executive Chairman | 11.3yrs | CN¥2.05m | 0.95% CN¥ 21.1m | |
| CEO & Executive Director | 1.8yrs | CN¥655.00k | keine Daten | |
| General Manager of Dental Business Division & Executive Director | less than a year | CN¥717.00k | keine Daten | |
| Independent Non-Executive Director | 2.5yrs | CN¥270.00k | keine Daten | |
| Independent Non-Executive Director | 5.4yrs | keine Daten | keine Daten | |
| Non-Executive Director | 3.5yrs | CN¥184.00k | keine Daten | |
| Independent Non-Executive Director | less than a year | keine Daten | keine Daten |
2.5yrs
Durchschnittliche Betriebszugehörigkeit
60yo
Durchschnittliches Alter
Erfahrener Vorstand: 1345Die Vorstandsmitglieder gelten nicht als erfahren ( 2.4 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.